Tag: ACE 083


Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease

Acceleron announced that in the second half of 2017 it plans to initiate a Phase 2 clinical trial of ACE-083, the Company’s locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT). This drug whose purpose is to both reinforce and raise locally the volume of the leg muscle has been already

Read More »
Join our mailing list. Always stay up to date.